IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–15 (cancelled).

16 (currently amended). A **therapeutic** combination ~~**preparation**~~ comprising (a) a compound having the formula



wherein

n is a number from 1 to 5;

R2 is OA, and R3 and R4 are each independently selected from H and OA, where A is H, C_{1-3} alkyl or a group



where R6 and R7 are each independently alkyl or aryl;

R5 is C_{1-3} alkyl;

R1 is a group



where X is S, O or NH;

or a racemate or pure (R)- or (S)-enantiomer thereof, or a physiologically acceptable salt thereof; and (b) ~~**at least one further**~~ **one or more additional** active ingredient**s** ~~**selected from the group consisting of**~~ **comprising one or more** antidepressants, antipsychotics, sedatives, anxiolytics ~~**and**~~ **and/or** anti-migraine agents.

17 (previously presented). A method for treating depression in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound having the formula



wherein

n is a number from 1 to 5;

R2 is OA, and R3 and R4 are each independently selected from H and OA, where A is H, C_{1-3} alkyl or a group



where R6 and R7 are each independently alkyl or aryl;

R5 is C_{1-3} alkyl;

R1 is a group



where X is S, O or NH;

or a racemate or pure (R)- or (S)-enantiomer thereof, or a physiologically acceptable salt thereof.

18 (previously presented). The method of Claim 17, wherein, in the formula for said compound, R3 and R4 are both H.

19 (previously presented). The method of Claim 17, wherein, in the formula for said compound, A is H or a group



where R6 is C_{1-12} alkyl, phenyl or methoxyphenyl.

20 (previously presented). The method of Claim 17, wherein, in the formula for said compound, n is a number from 1 to 3 and R5 is C_3 alkyl.

21 (previously presented). The method of Claim 17, wherein, in the formula for said compound, X is S.

22 (previously presented). The method of Claim 21, wherein, in the formula for said compound, R1 is a 2-thienyl group.

23 (previously presented). The method of Claim 17, wherein the compound is 5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol.

24 (previously presented). The method of Claim 17, wherein the mammal is human.

25 (currently amended). The method of Claim 24, wherein the depression is an endogenous depression ~~or an organic depression not associated with Parkinson's disease~~.

26 (currently amended). The method of Claim **[[24]]** **25**, wherein the **endogenous** depression is a unipolar depression (major depression) or a depressive phase of a manic-depressive disorder.

27 (currently amended). The method of Claim **[[24]]** **38**, wherein the **somatogenic** depression is an organic depression not associated with Parkinson's disease.

28 (currently amended). The method of Claim **[[24]]** **38**, wherein the **somatogenic** depression is an organic depression associated with Parkinson's disease.

29 (previously presented). The method of Claim 28, wherein co-medication with another antidepressant is absent.

30 (previously presented). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered parenterally, transdermally or mucosally.

31 (previously presented). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof, or salt thereof, is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration.

32 (previously presented). The method of Claim 24, wherein the active ingredient is administered transdermally via a plaster having the active ingredient in a matrix comprising an adhesive polymer.

33 (previously presented). The method of Claim 24, wherein the active ingredient is administered transdermally and wherein a substantially constant plasma level of the active ingredient is established.

34 (currently amended). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof, or salt thereof, is administered in a dose of 0.5 to **about** 50 mg per day.

35 (currently amended). The method of Claim 17, further comprising administering to the mammal ~~**an additional active ingredient selected from the group consisting of**~~ **one or more** antidepressants~~**, antipsychotics, sedatives, anxiolytics and anti-migraine agents**~~.

36 (currently amended). The combination ~~**preparation**~~ of Claim 16, wherein the **one or more** additional active ingredient**s** ~~**comprises an**~~ **comprise one or more** antidepressants ~~**selected from the group consisting of**~~ **comprising one or more** selective serotonin reuptake inhibitors, mixed serotonin and noradrenaline reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor and/or serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists ~~**and**~~ **and/or** modulators of the hypothalamus-hypophysis-adrenal axis.

37 (new). The method of Claim 23, wherein at least 90 mol % of the compound is in the form of the S enantiomer.

38 (new). The method of Claim 24, wherein the depression is a somatogenic depression.

39 (new). The method of Claim 27, wherein the organic depression is associated with brain tumor, migraine, epilepsy, brain paralysis, arteriosclerosis of the brain, brain trauma, meningitis, stroke, Parkinson Plus syndrome, dementia and/or cerebrovascular disease.

40 (new). The method of Claim 27, wherein the depression is associated with Alzheimer's disease.

41 (new). The method of Claim 38, wherein the somatogenic depression is a symptomatic depression.

42 (new). The method of Claim 41, wherein the symptomatic depression is associated with circulatory illness, hypothyroidism, hormone disorder, infectious disease, cancer and/or liver disease.

43 (new). The method of Claim 38, wherein the somatogenic depression is a pharmacogenic depression.

44 (new). The method of Claim 43, wherein the pharmacogenic depression is associated with alcohol, medication and/or drug misuse.

45 (new). The method of Claim 24, wherein the depression is a psychogenic depression.

46 (new). The method of Claim 45, wherein the psychogenic depression comprises at least one of exhaustion depression, neurotic depression and reactive depression as a result of current conflicts or events.

47 (new). The method of Claim 24, wherein the depression is a specific life situation depression, comprising at least one of postpartum depression, old-age depression, childhood depression, seasonal depression and pubertal depression.

48 (new). The method of Claim 17, wherein the depression is associated with an affective disorder.

49 (new). The method of Claim 48, wherein the affective disorder comprises a recurrent depressive disorder and/or depressive phases in bipolar affective disorder.

50 (new). The method of Claim 17, wherein the depression manifests as depressive

symptoms accompanying at least one anxiety disorder, adjustment disorder and/or organic brain disease.

51 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered in a dose of 0.1 to about 50 mg per day.

52 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered in a dose of 0.2 to 40 mg per day.

53 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered in a dose of 0.4 to 20 mg per day.

54 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered in a dose of 0.5 to 10 mg per day.

55 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof or salt thereof, is administered in a dose of 0.5 to 5 mg per day.

56 (new). The method of Claim 35, wherein the one or more antidepressants comprise one or more serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis.

57 (new). The method of Claim 56, wherein the one or more antidepressants comprise at least one of sertraline, citalopram, paroxetine, fluoxetine, venlaxafine, milnacipram, mirtazapine, amitryptiline, imipramine, reboxetine, tranylcypramine, clorgyline, mirtazapine and/or nefazodone.

58 (new). The method of Claim 17, further comprising administering to the mammal one or more antipsychotics.

59 (new). The method of Claim 58, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol,

zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

60 (new). The method of Claim 17, further comprising administering to the mammal one or more sedatives.

61 (new). The method of Claim 60, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon.

62 (new). The method of Claim 17, further comprising administering to the mammal one or more anxiolytics.

63 (new). The method of Claim 62, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

64 (new). The method of Claim 17, further comprising administering to the mammal one or more anti-migraine agents.

65 (new). The method of Claim 64, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol.

66 (new). The method of Claim 17, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein said compound, or racemate or enantiomer thereof or salt thereof, and the at least one additional active ingredient are provided in separate dosage forms for administration by the same or different routes at the same or different times.

67 (new). The method of Claim 17, further comprising administering to the mammal at least

one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein said compound and the at least one additional active ingredient are administered in a single dosage form.

68 (new). The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more antipsychotics.

69 (new). The combination of Claim 68, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

70 (new). The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more sedatives.

71 (new). The combination of Claim 70, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon.

72 (new). The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more anxiolytics.

73 (new). The combination of Claim 72, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

74 (new). The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more anti-migraine agents.

75 (new). The combination of Claim 74, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan,

naratriptan and/or paracetamol.

76 (new). The combination of Claim 16, wherein said compound, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in separate dosage forms adapted for administration by the same or different routes at the same or different times.

77 (new). The combination of Claim 16, wherein said compound, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in a single dosage form.